Claims:

1.(Cancelled) A compound selected from the group consisting of



;



and



wherein R_1, R_7 and R_8 are independently selected from the group consisting of H, halo, alkyl, haloalkyl and hydroxy;

R_3 is hydroxy or -$OCONH_2$; and

R_4 is hydroxy or carbonyl.

2. (Cancelled) The compound of claim 1 having the general structure:



or



wherein R_1, R_7 and R_8 are independently selected from the group consisting of H, halo, alkyl, haloalkyl and hydroxy;

R_3 is hydroxy or -$OCONH_2$; and

R_4 is hydroxy or carbonyl.

3. (Cancelled) The compound of claim 2 wherein R_7 and R_8 are H;

R_1 is H or F; and

R_4 is hydroxy or carbonyl.

4. (Cancelled) The compound of claim 1 having the general structure:



wherein R_1 is selected from the group consisting of halo, haloalkyl and hydroxy;

R_7 and R_8 are independently selected from the group consisting of H, halo, alkyl, haloalkyl and hydroxy; and

R_3 is hydroxy or -$OCONH_2$.

5. (Cancelled) The compound of claim 4 wherein R_7 and R_8 are H;

R_1 is F; and

R_3 is hydroxy or -$OCONH_2$.

6. (Cancelled) The compound of claim 1 having the general structure



wherein R_1 is selected from the group consisting of H, halo, haloalkyl and hydroxy; and

R_3 is hydroxy or -$OCONH_2$.

7. (Cancelled) The compound of claim 6 wherein R_1 is H; and

R_3 is -$OCONH_2$.

8. (Cancelled) The compound of claim 1 having the general structure



wherein R_1 and R_7 are independently selected from the group consisting of H, halo, haloalkyl and hydroxy; and

R_4 is hydroxy or carbonyl.

9. (Cancelled) The compound of claim 8 wherein R_7 is H.

10. (Cancelled) The compound of claim 6 or 9 wherein R_1 is H or F.

11. (Cancelled) A method for treating a patient suffering from a neurological disorder, said method comprising the step of administering a composition comprising a compound selected from the group consisting of



;



and



wherein R_1, R_7 and R_8 are independently selected from the group consisting of H, halo, alkyl, haloalkyl and hydroxy;

R_3 is hydroxy or -$OCONH_2$; and

R_4 is hydroxy or carbonyl.

12. (Cancelled) The method of claim 11 wherein the composition is administered orally.

13. (Cancelled) The method of claim 12 wherein the unit dosage form of the composition comprises about 0.1 mg/kg to about 1 g/kg of said compound.

14. (Cancelled) The method of claim 13 wherein said compound has the general structure



wherein R_1 is selected from the group consisting of H, halo, haloalkyl and hydroxy; and

R_3 is hydroxy or -$OCONH_2$.

15. (Cancelled) The method of claim 14 wherein R_1 is H; and

R_3 is -$OCONH_2$.

16. (Cancelled) A method for treating a patient suffering from tissue damage resulting from localized hypoxic conditions, said method comprising the step of administering a composition comprising a compound selected from the group consisting of



;



and



wherein R_1, R_7 and R_8 are independently selected from the group consisting of H, halo, alkyl, haloalkyl and hydroxy;

R_3 is hydroxy or -$OCONH_2$; and

R_4 is hydroxy or carbonyl.

17. (Cancelled) The method of claim 16 wherein said compound has the general structure



wherein R_1 is selected from the group consisting of H, halo, haloalkyl and hydroxy; and

R_3 is hydroxy or -$OCONH_2$.

18. (Cancelled) The method of claim 17 wherein R_1 is H; and

R_3 is -$OCONH_2$.

19. (Cancelled) The method of claim 16 wherein the localized hypoxic condition is caused by cerebral ischemia.

20. (Cancelled) The method of claim 16 wherein the localized hypoxic condition is caused by myocardial ischemia.

21. (Cancelled) The method of claim 16 wherein the composition is administered orally.

22. (Cancelled) The method of claim 16 wherein the composition is administered parenterally.

23. (Cancelled) The method of claim 22 wherein the unit dosage form of the composition comprises about 1.0 mg/kg to about 1 g/kg of said compound and the composition is administered intravenously.

24. (Cancelled) A pharmaceutical composition comprising a compound selected from the group consisting of



;



and



wherein R_1, R_7 and R_8 are independently selected from the group consisting of H, halo, alkyl, haloalkyl and hydroxy;

R_3 is hydroxy or -$OCONH_2$; and

R_4 is hydroxy or carbonyl, and a pharmaceutically acceptable carrier.

25. (Cancelled) The composition of claim 24 wherein said compound has the general structure



wherein R_1 is selected from the group consisting of H, halo, haloalkyl and hydroxy; and

R_3 is hydroxy or -$OCONH_2$.

26. (Cancelled) The composition of claim 25 wherein R_1 is selected from the group consisting of halo, haloalkyl and hydroxy.

27. (Cancelled) The composition of claim 25 wherein R_1 is H; and

R_3 is $-OCONH_2$.

28. (Cancelled) The composition of claim 24 wherein said compound has the general structure



wherein R_1 and R_7 are independently selected from the group consisting of H, halo, haloalkyl and hydroxy;

and R_3 is hydroxy or $-OCONH_2$.

29. (Cancelled) The composition of claim 28 wherein R_7 is H.

30. (Cancelled) The composition of claim 25, 28 or 29 wherein R_1 is H or F.

31.(NEW) A compound of the formula:



wherein: R_2 is halo; and R_3 is hydroxy or $-OCONH_2$.

32.(NEW) The compound of claim 31 wherein R_2 is chloro or fluoro.

33.(NEW) The compound of claim 31 wherein R_2 is fluoro.

34.(NEW) The compound of claim 31 wherein R_3 is hydroxy.

35.(NEW) The compound of claim 31 wherein R_3 is $-OCONH_2$.

36.(NEW) The compound of claim 34 wherein R_2 is chloro or fluoro.

37.(NEW) The compound of claim 34 wherein R_2 is fluoro.

38.(NEW) The compound of claim 35 wherein R_2 is chloro or fluoro.

39.(NEW) The compound of claim 35 wherein R_2 is fluoro.

40.(NEW) A composition comprising a compound as described in claim 31, and a pharmaceutically acceptable carrier.

41. (NEW) A composition comprising a compound as described in claim 39, and a pharmaceutically acceptable carrier.

42.(NEW) A method for treating a patient suffering from a neurological disorder, comprising administering to the patient, an effective amount of a compound as described in claim 31.

43.(NEW) A method for treating a patient suffering from tissue damage resulting from localized hypoxic conditions comprising

administering to the patient, an effective amount of a compound as described in claim 31.

44.(NEW) A method for treating a patient suffering from a neurological disorder, comprising administering to the patient, an effective amount of a compound as described in claim 39.

45.(NEW) A method for treating a patient suffering from tissue damage resulting from localized hypoxic conditions comprising administering to the patient, an effective amount of a compound as described in claim 39.